Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C.The ...

Y MABS THERAPEUTICS ($YMAB) posted quarterly earnings results on Tuesday, March 4th. The company reported earnings of -$0.15 per share, missing estimates of -$0.13 by ...

Y-mAbs Therapeutics, Inc. (YMAB) has been on a downward spiral lately with significant selling pressure. After declining 25.7% over the past four weeks, the stock looks well positioned for a trend ...

Y-mAbs Therapeutics, Inc. (YMAB) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home ...